Cassava Sciences | DEF 14A: Definitive information statements
Cassava Sciences | ARS: Annual Report to Security Holders
Cassava Sciences | 10-K: Annual report
Cassava Sciences | 8-K: Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
Cassava Sciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.51%)
Cassava Sciences | 8-K: No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
Cassava Sciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Remi Barbier(5.7%)
Cassava Sciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.2%)
Cassava Sciences | CERT: Others
Cassava Sciences | 424B2: Prospectus
Cassava Sciences | 8-A12B: Registration of a class of securities on a national securities exchange
Cassava Sciences | 8-K: Entry into Material Definitive Agreements
Cassava Sciences | 8-A12G: Others
Cassava Sciences | 8-K: Current report
Cassava Sciences | 8-K: Current report
Cassava Sciences | 4: Statement of changes in beneficial ownership of securities-Director Nicaise Claude
Cassava Sciences | 3: Initial statement of beneficial ownership of securities-Director Nicaise Claude
Cassava Sciences | 4: Statement of changes in beneficial ownership of securities-Director Gravier Pierre
Cassava Sciences | 4: Statement of changes in beneficial ownership of securities-Director Anderson Robert Eugene Jr
Cassava Sciences | 3: Initial statement of beneficial ownership of securities-Director Gravier Pierre
No Data